CN Patent

CN102656159B — Cgrp受体拮抗剂

Assigned to Bristol Myers Squibb Co · Expires 2015-07-01 · 11y expired

What this patent protects

本发明一般地涉及式I的新颖化合物，包括药学上可接受的盐，其是CGRP受体拮抗剂。本发明也涉及药物组合物及使用所述化合物来治疗CGRP相关性障碍的方法，所述CGRP相关性障碍包括偏头痛及其它头痛、神经源性血管舒张、神经源性炎症、热伤、循环性休克、与绝经有关的潮红、呼吸道炎性疾病如哮喘及慢性阻塞性肺疾病(COPD)。

USPTO Abstract

本发明一般地涉及式I的新颖化合物，包括药学上可接受的盐，其是CGRP受体拮抗剂。本发明也涉及药物组合物及使用所述化合物来治疗CGRP相关性障碍的方法，所述CGRP相关性障碍包括偏头痛及其它头痛、神经源性血管舒张、神经源性炎症、热伤、循环性休克、与绝经有关的潮红、呼吸道炎性疾病如哮喘及慢性阻塞性肺疾病(COPD)。

Drugs covered by this patent

Nurtec Odt (Rimegepant Sulfate) · Pfizer

Patent Metadata

Patent number: CN102656159B
Jurisdiction: CN
Classification: —
Expires: 2015-07-01
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.